Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Trump Buys SpaceX Shares After Record IPO 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Nvidia Options Price in $280 Billion Earnings Swing 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Tesla Raises Cybertruck Prices by $5,000 in US 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Add as a preferred source on Google
MEDFORD, N.Y., April 26, 2018 -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, announced today that it will release financial results for the first quarter 2018 after the close of trading on Wednesday, May 9, 2018. The Company’s management team will host a corresponding conference call beginning at 4:30 pm ET.
Investors interested in listening to the conference call may do so by dialing 877-407-0778 from the US or 201-689-8565 from outside the US. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at www.chembio.com. A telephone replay will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 28132 until 4:30pm ET on Wednesday, May 16, 2018.
Contact:
Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
[email protected]
